Andres Henao Martinez
Concepts (528)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chagas Disease | 13 | 2023 | 42 | 6.700 |
Why?
| | Chagas Cardiomyopathy | 7 | 2023 | 27 | 4.050 |
Why?
| | Meningitis, Cryptococcal | 8 | 2024 | 34 | 3.380 |
Why?
| | Opportunistic Infections | 5 | 2026 | 47 | 3.340 |
Why?
| | Cryptococcosis | 6 | 2023 | 31 | 3.150 |
Why?
| | Antifungal Agents | 11 | 2026 | 151 | 2.830 |
Why?
| | Glucocorticoids | 5 | 2026 | 531 | 2.270 |
Why?
| | Trypanosoma cruzi | 6 | 2023 | 39 | 2.230 |
Why?
| | Mycoses | 3 | 2026 | 88 | 1.910 |
Why?
| | Pneumonia, Pneumocystis | 2 | 2025 | 34 | 1.730 |
Why?
| | Cryptococcus neoformans | 4 | 2024 | 21 | 1.730 |
Why?
| | Immunocompromised Host | 8 | 2026 | 202 | 1.660 |
Why?
| | Invasive Pulmonary Aspergillosis | 2 | 2023 | 7 | 1.580 |
Why?
| | HIV Infections | 11 | 2026 | 3193 | 1.500 |
Why?
| | Travel | 6 | 2021 | 136 | 1.480 |
Why?
| | Strongyloidiasis | 2 | 2024 | 4 | 1.320 |
Why?
| | Cryptococcus | 2 | 2024 | 16 | 1.300 |
Why?
| | Candidemia | 3 | 2025 | 15 | 1.290 |
Why?
| | Humans | 119 | 2026 | 145474 | 1.220 |
Why?
| | Fluconazole | 4 | 2025 | 23 | 1.210 |
Why?
| | Transplant Recipients | 2 | 2025 | 181 | 1.190 |
Why?
| | Stroke, Lacunar | 2 | 2019 | 4 | 1.170 |
Why?
| | Adult | 49 | 2026 | 40777 | 1.170 |
Why?
| | Anti-Bacterial Agents | 10 | 2025 | 1923 | 1.150 |
Why?
| | Hospitalization | 8 | 2026 | 2460 | 1.080 |
Why?
| | Transients and Migrants | 3 | 2023 | 27 | 1.080 |
Why?
| | Tuberculosis | 2 | 2022 | 283 | 1.070 |
Why?
| | Cardiomyopathies | 2 | 2021 | 335 | 1.020 |
Why?
| | Yellow Fever | 3 | 2022 | 9 | 0.990 |
Why?
| | Male | 57 | 2026 | 72842 | 0.980 |
Why?
| | Middle Aged | 35 | 2026 | 36215 | 0.970 |
Why?
| | Candida | 3 | 2025 | 45 | 0.960 |
Why?
| | Echinococcosis, Hepatic | 1 | 2026 | 2 | 0.950 |
Why?
| | Sporotrichosis | 1 | 2026 | 6 | 0.940 |
Why?
| | Echinococcosis | 1 | 2026 | 9 | 0.940 |
Why?
| | Bacteremia | 5 | 2023 | 222 | 0.930 |
Why?
| | Pneumocystis carinii | 1 | 2025 | 12 | 0.930 |
Why?
| | Coccidioidomycosis | 1 | 2025 | 7 | 0.930 |
Why?
| | Risk Factors | 18 | 2026 | 10885 | 0.920 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2019 | 194 | 0.910 |
Why?
| | Rubella | 1 | 2025 | 23 | 0.910 |
Why?
| | Mumps | 1 | 2025 | 21 | 0.900 |
Why?
| | Measles | 1 | 2025 | 46 | 0.880 |
Why?
| | Cytomegalovirus | 1 | 2026 | 168 | 0.880 |
Why?
| | Central Nervous System Neoplasms | 2 | 2018 | 177 | 0.860 |
Why?
| | Macrolides | 1 | 2025 | 67 | 0.860 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 134 | 0.840 |
Why?
| | Parasitemia | 2 | 2015 | 15 | 0.840 |
Why?
| | United States | 24 | 2026 | 16098 | 0.840 |
Why?
| | Pneumocystis | 1 | 2024 | 8 | 0.840 |
Why?
| | Cytomegalovirus Infections | 1 | 2026 | 206 | 0.820 |
Why?
| | DNA, Viral | 1 | 2026 | 356 | 0.820 |
Why?
| | Pulmonary Aspergillosis | 1 | 2023 | 4 | 0.800 |
Why?
| | Immunosuppressive Agents | 2 | 2025 | 838 | 0.800 |
Why?
| | Nitroimidazoles | 1 | 2023 | 16 | 0.800 |
Why?
| | Aged | 22 | 2026 | 26153 | 0.800 |
Why?
| | Drug Hypersensitivity | 1 | 2025 | 90 | 0.790 |
Why?
| | Myocarditis | 2 | 2016 | 102 | 0.780 |
Why?
| | Anemia, Aplastic | 1 | 2023 | 42 | 0.770 |
Why?
| | Female | 47 | 2026 | 78844 | 0.770 |
Why?
| | Pneumonia, Viral | 7 | 2020 | 389 | 0.770 |
Why?
| | Coronavirus Infections | 7 | 2020 | 383 | 0.760 |
Why?
| | Organ Transplantation | 2 | 2025 | 251 | 0.760 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2024 | 130 | 0.760 |
Why?
| | Enterobacteriaceae Infections | 2 | 2013 | 42 | 0.740 |
Why?
| | Zoonoses | 2 | 2024 | 38 | 0.730 |
Why?
| | Virus Diseases | 1 | 2024 | 216 | 0.720 |
Why?
| | Osteomyelitis | 2 | 2025 | 145 | 0.690 |
Why?
| | Antigens, Fungal | 2 | 2024 | 28 | 0.690 |
Why?
| | Retrospective Studies | 17 | 2026 | 17291 | 0.690 |
Why?
| | Neglected Diseases | 1 | 2020 | 5 | 0.660 |
Why?
| | Mycobacterium Infections | 2 | 2018 | 55 | 0.660 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 342 | 0.660 |
Why?
| | Hepatitis | 1 | 2020 | 43 | 0.650 |
Why?
| | Incidence | 5 | 2026 | 2923 | 0.630 |
Why?
| | Hantavirus Pulmonary Syndrome | 1 | 2020 | 5 | 0.630 |
Why?
| | Heart Aneurysm | 1 | 2019 | 12 | 0.610 |
Why?
| | Massive Hepatic Necrosis | 1 | 2019 | 3 | 0.600 |
Why?
| | Epidemics | 1 | 2020 | 96 | 0.590 |
Why?
| | Aneurysm, False | 1 | 2019 | 46 | 0.590 |
Why?
| | Hepatitis A | 1 | 2019 | 25 | 0.590 |
Why?
| | Neisseria gonorrhoeae | 1 | 2019 | 29 | 0.580 |
Why?
| | Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 3 | 0.570 |
Why?
| | Sarcoma, Myeloid | 1 | 2018 | 4 | 0.570 |
Why?
| | Hematoma, Subdural | 1 | 2018 | 20 | 0.570 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 37 | 0.540 |
Why?
| | Malaria, Falciparum | 1 | 2018 | 32 | 0.540 |
Why?
| | Chromoblastomycosis | 1 | 2017 | 1 | 0.540 |
Why?
| | Gonorrhea | 1 | 2019 | 63 | 0.540 |
Why?
| | Skin | 3 | 2022 | 753 | 0.540 |
Why?
| | Population Groups | 1 | 2018 | 56 | 0.540 |
Why?
| | Hand Dermatoses | 1 | 2017 | 7 | 0.530 |
Why?
| | Fever | 2 | 2020 | 319 | 0.530 |
Why?
| | Dyspnea | 1 | 2019 | 250 | 0.530 |
Why?
| | Renal Insufficiency | 1 | 2020 | 172 | 0.530 |
Why?
| | Meningioma | 1 | 2018 | 88 | 0.520 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 95 | 0.520 |
Why?
| | Delayed Diagnosis | 1 | 2018 | 100 | 0.520 |
Why?
| | Medically Uninsured | 1 | 2018 | 132 | 0.520 |
Why?
| | Abscess | 1 | 2018 | 77 | 0.510 |
Why?
| | Milk | 1 | 2018 | 119 | 0.510 |
Why?
| | Latin America | 6 | 2022 | 96 | 0.490 |
Why?
| | Heart Failure | 2 | 2022 | 2326 | 0.490 |
Why?
| | Poliomyelitis | 3 | 2022 | 35 | 0.490 |
Why?
| | Pandemics | 10 | 2023 | 1707 | 0.490 |
Why?
| | Prisons | 4 | 2021 | 85 | 0.490 |
Why?
| | Trichuriasis | 1 | 2016 | 4 | 0.480 |
Why?
| | Pregnancy Complications, Parasitic | 1 | 2016 | 9 | 0.480 |
Why?
| | Lymphocytosis | 1 | 2016 | 11 | 0.480 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2016 | 24 | 0.470 |
Why?
| | Parotid Neoplasms | 1 | 2016 | 15 | 0.470 |
Why?
| | Enterobacteriaceae | 2 | 2013 | 44 | 0.470 |
Why?
| | Databases, Factual | 4 | 2025 | 1490 | 0.470 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2016 | 20 | 0.470 |
Why?
| | Diphyllobothriasis | 1 | 2015 | 2 | 0.460 |
Why?
| | Diphyllobothrium | 1 | 2015 | 2 | 0.460 |
Why?
| | Colombia | 4 | 2020 | 42 | 0.460 |
Why?
| | Occupational Diseases | 1 | 2017 | 165 | 0.460 |
Why?
| | Plasmablastic Lymphoma | 1 | 2015 | 8 | 0.460 |
Why?
| | Insect Vectors | 1 | 2015 | 39 | 0.450 |
Why?
| | Young Adult | 13 | 2026 | 14218 | 0.450 |
Why?
| | Gamma Rays | 1 | 2015 | 57 | 0.450 |
Why?
| | Transplants | 1 | 2015 | 38 | 0.450 |
Why?
| | Plasma Cells | 1 | 2015 | 79 | 0.450 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 269 | 0.430 |
Why?
| | Heart Ventricles | 1 | 2019 | 756 | 0.420 |
Why?
| | Anemia | 1 | 2016 | 191 | 0.420 |
Why?
| | Bone Marrow | 1 | 2016 | 306 | 0.420 |
Why?
| | Propensity Score | 3 | 2026 | 377 | 0.420 |
Why?
| | Lymphoma | 1 | 2016 | 237 | 0.410 |
Why?
| | Treatment Outcome | 13 | 2026 | 11772 | 0.410 |
Why?
| | Thrombocytopenia | 1 | 2016 | 204 | 0.410 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2023 | 440 | 0.410 |
Why?
| | Anaphylaxis | 2 | 2025 | 102 | 0.400 |
Why?
| | Leprosy | 2 | 2026 | 25 | 0.400 |
Why?
| | Myocardial Contraction | 1 | 2015 | 293 | 0.390 |
Why?
| | Environmental Exposure | 1 | 2018 | 578 | 0.390 |
Why?
| | Research | 1 | 2016 | 430 | 0.390 |
Why?
| | Thrombocytosis | 1 | 2013 | 6 | 0.380 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2013 | 4 | 0.380 |
Why?
| | Betacoronavirus | 6 | 2020 | 288 | 0.380 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2013 | 14 | 0.380 |
Why?
| | Animals | 17 | 2026 | 38030 | 0.380 |
Why?
| | Amphotericin B | 2 | 2025 | 36 | 0.380 |
Why?
| | Sepsis | 3 | 2026 | 664 | 0.370 |
Why?
| | Herpesvirus 8, Human | 1 | 2013 | 67 | 0.370 |
Why?
| | Antigens, Protozoan | 1 | 2012 | 32 | 0.370 |
Why?
| | Acinetobacter Infections | 1 | 2012 | 15 | 0.370 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2023 | 251 | 0.370 |
Why?
| | Proctitis | 1 | 2012 | 6 | 0.360 |
Why?
| | Acinetobacter | 1 | 2012 | 16 | 0.360 |
Why?
| | H-2 Antigens | 1 | 2012 | 111 | 0.360 |
Why?
| | Herpes Genitalis | 1 | 2012 | 17 | 0.360 |
Why?
| | Herpesvirus 2, Human | 1 | 2012 | 27 | 0.360 |
Why?
| | Cellulitis | 1 | 2012 | 54 | 0.360 |
Why?
| | Isoxazoles | 1 | 2012 | 56 | 0.350 |
Why?
| | Yellow Fever Vaccine | 2 | 2022 | 7 | 0.350 |
Why?
| | Acyclovir | 1 | 2012 | 98 | 0.350 |
Why?
| | Severe Dengue | 1 | 2011 | 11 | 0.350 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 148 | 0.340 |
Why?
| | Emigration and Immigration | 2 | 2022 | 66 | 0.330 |
Why?
| | Poliovirus | 2 | 2022 | 73 | 0.330 |
Why?
| | Healthcare Disparities | 3 | 2024 | 735 | 0.320 |
Why?
| | B-Lymphocytes | 1 | 2016 | 870 | 0.320 |
Why?
| | Pancreatitis | 1 | 2011 | 146 | 0.310 |
Why?
| | Moraxella | 1 | 2009 | 4 | 0.310 |
Why?
| | Moraxellaceae Infections | 1 | 2009 | 3 | 0.310 |
Why?
| | Prognosis | 4 | 2026 | 4316 | 0.300 |
Why?
| | Repressor Proteins | 1 | 2013 | 429 | 0.300 |
Why?
| | Acute Lung Injury | 1 | 2013 | 305 | 0.300 |
Why?
| | Lung Diseases | 2 | 2018 | 780 | 0.300 |
Why?
| | Comorbidity | 4 | 2026 | 1661 | 0.290 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3904 | 0.290 |
Why?
| | Global Health | 4 | 2026 | 403 | 0.290 |
Why?
| | Lupus Nephritis | 1 | 2009 | 67 | 0.290 |
Why?
| | Antibodies, Viral | 2 | 2025 | 674 | 0.290 |
Why?
| | Aged, 80 and over | 6 | 2025 | 8333 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2588 | 0.290 |
Why?
| | Pulmonary Emphysema | 1 | 2011 | 277 | 0.280 |
Why?
| | Arthritis, Infectious | 1 | 2009 | 76 | 0.280 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1321 | 0.280 |
Why?
| | Presenilin-1 | 1 | 2008 | 34 | 0.270 |
Why?
| | Fatal Outcome | 2 | 2019 | 305 | 0.270 |
Why?
| | Seroepidemiologic Studies | 2 | 2025 | 171 | 0.270 |
Why?
| | Staphylococcal Infections | 3 | 2023 | 391 | 0.270 |
Why?
| | Immunoglobulin G | 3 | 2023 | 892 | 0.270 |
Why?
| | Engineering | 1 | 2018 | 31 | 0.270 |
Why?
| | Social Responsibility | 1 | 2018 | 53 | 0.260 |
Why?
| | Mycobacterium | 2 | 2018 | 101 | 0.250 |
Why?
| | Echinocandins | 2 | 2023 | 8 | 0.250 |
Why?
| | Acute Kidney Injury | 2 | 2026 | 875 | 0.250 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2018 | 117 | 0.240 |
Why?
| | Vaccination | 3 | 2025 | 1426 | 0.240 |
Why?
| | Echinococcus | 1 | 2026 | 1 | 0.240 |
Why?
| | Public Health | 3 | 2020 | 572 | 0.240 |
Why?
| | Babesiosis | 1 | 2026 | 4 | 0.240 |
Why?
| | Coccidioides | 1 | 2025 | 6 | 0.230 |
Why?
| | Antiviral Agents | 1 | 2012 | 769 | 0.230 |
Why?
| | Attitude | 1 | 2018 | 259 | 0.230 |
Why?
| | HIV | 2 | 2018 | 251 | 0.230 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1963 | 0.230 |
Why?
| | Tick Bites | 1 | 2025 | 6 | 0.230 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2025 | 48 | 0.230 |
Why?
| | Erythema Nodosum | 1 | 2025 | 6 | 0.220 |
Why?
| | Mental Disorders | 2 | 2025 | 1163 | 0.220 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 614 | 0.220 |
Why?
| | Electrocardiography | 2 | 2019 | 665 | 0.220 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1061 | 0.220 |
Why?
| | Paresthesia | 1 | 2025 | 14 | 0.220 |
Why?
| | Clarithromycin | 1 | 2025 | 24 | 0.220 |
Why?
| | Leprosy, Lepromatous | 1 | 2025 | 8 | 0.220 |
Why?
| | Erythromycin | 1 | 2025 | 19 | 0.220 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.220 |
Why?
| | Shock, Septic | 2 | 2021 | 227 | 0.220 |
Why?
| | Gelatin | 1 | 2025 | 56 | 0.220 |
Why?
| | Uveitis, Anterior | 1 | 2025 | 27 | 0.220 |
Why?
| | Cross Reactions | 1 | 2025 | 130 | 0.220 |
Why?
| | Insect Bites and Stings | 1 | 2024 | 13 | 0.220 |
Why?
| | Prednisone | 1 | 2025 | 224 | 0.210 |
Why?
| | Strongyloides stercoralis | 1 | 2024 | 2 | 0.210 |
Why?
| | Azithromycin | 1 | 2025 | 101 | 0.210 |
Why?
| | Teicoplanin | 2 | 2023 | 14 | 0.210 |
Why?
| | Colorado | 3 | 2020 | 4553 | 0.200 |
Why?
| | World Health Organization | 2 | 2021 | 104 | 0.200 |
Why?
| | Refugees | 1 | 2025 | 83 | 0.200 |
Why?
| | Peru | 2 | 2024 | 60 | 0.200 |
Why?
| | Observational Studies as Topic | 2 | 2025 | 133 | 0.200 |
Why?
| | Meningoencephalitis | 1 | 2023 | 24 | 0.200 |
Why?
| | Toxoplasmosis | 1 | 2023 | 43 | 0.200 |
Why?
| | Toxoplasma | 1 | 2023 | 49 | 0.200 |
Why?
| | Voriconazole | 1 | 2023 | 21 | 0.200 |
Why?
| | Alanine | 1 | 2024 | 169 | 0.190 |
Why?
| | Rabies Vaccines | 1 | 2022 | 3 | 0.190 |
Why?
| | Rabies | 1 | 2022 | 4 | 0.190 |
Why?
| | Georgia | 2 | 2025 | 79 | 0.190 |
Why?
| | Glycopeptides | 1 | 2023 | 44 | 0.190 |
Why?
| | Antiparasitic Agents | 1 | 2022 | 4 | 0.190 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 2121 | 0.190 |
Why?
| | Cohort Studies | 4 | 2026 | 6013 | 0.190 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1044 | 0.180 |
Why?
| | Pyridones | 1 | 2024 | 209 | 0.180 |
Why?
| | Americas | 1 | 2022 | 27 | 0.180 |
Why?
| | Students | 1 | 2018 | 651 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 969 | 0.180 |
Why?
| | Disease Notification | 1 | 2022 | 16 | 0.180 |
Why?
| | Drug Monitoring | 1 | 2026 | 401 | 0.180 |
Why?
| | Tenofovir | 1 | 2024 | 301 | 0.180 |
Why?
| | Travel Medicine | 2 | 2020 | 5 | 0.180 |
Why?
| | Italy | 1 | 2022 | 116 | 0.180 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 168 | 0.180 |
Why?
| | Pregnancy | 4 | 2024 | 7202 | 0.170 |
Why?
| | Dog Diseases | 1 | 2022 | 86 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 4 | 2019 | 2769 | 0.170 |
Why?
| | Staphylococcal Skin Infections | 2 | 2012 | 40 | 0.170 |
Why?
| | Alzheimer Disease | 1 | 2008 | 630 | 0.170 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 237 | 0.170 |
Why?
| | Precision Medicine | 1 | 2026 | 459 | 0.170 |
Why?
| | Population Dynamics | 1 | 2022 | 142 | 0.170 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1327 | 0.170 |
Why?
| | Leishmania guyanensis | 1 | 2020 | 1 | 0.160 |
Why?
| | Phosphorylcholine | 1 | 2020 | 19 | 0.160 |
Why?
| | Antiprotozoal Agents | 1 | 2020 | 15 | 0.160 |
Why?
| | Personal Protective Equipment | 1 | 2021 | 58 | 0.160 |
Why?
| | Pericarditis | 1 | 2020 | 11 | 0.160 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2020 | 14 | 0.160 |
Why?
| | Child | 8 | 2026 | 22707 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1217 | 0.160 |
Why?
| | Case-Control Studies | 3 | 2018 | 3623 | 0.160 |
Why?
| | Rural Population | 2 | 2022 | 659 | 0.160 |
Why?
| | Anti-Inflammatory Agents | 1 | 2024 | 477 | 0.160 |
Why?
| | Vaccines | 1 | 2025 | 388 | 0.160 |
Why?
| | Weight Gain | 1 | 2024 | 561 | 0.160 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 48 | 0.160 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 39 | 0.150 |
Why?
| | Africa | 1 | 2020 | 119 | 0.150 |
Why?
| | Late Onset Disorders | 1 | 2019 | 2 | 0.150 |
Why?
| | Immunization, Secondary | 1 | 2020 | 92 | 0.150 |
Why?
| | Bolivia | 1 | 2019 | 63 | 0.150 |
Why?
| | Developing Countries | 1 | 2022 | 316 | 0.150 |
Why?
| | Proteinuria | 1 | 2020 | 104 | 0.150 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2020 | 71 | 0.150 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2378 | 0.150 |
Why?
| | Infection Control | 1 | 2021 | 173 | 0.150 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 11 | 0.150 |
Why?
| | Cryptococcus gattii | 1 | 2018 | 1 | 0.140 |
Why?
| | Medical Errors | 1 | 2020 | 119 | 0.140 |
Why?
| | Dermatitis | 1 | 2018 | 20 | 0.140 |
Why?
| | Acute Disease | 2 | 2012 | 1036 | 0.140 |
Why?
| | Vulnerable Populations | 1 | 2020 | 176 | 0.140 |
Why?
| | Speech Disorders | 1 | 2018 | 29 | 0.140 |
Why?
| | Echocardiography | 2 | 2020 | 647 | 0.140 |
Why?
| | Prospective Studies | 4 | 2023 | 8057 | 0.140 |
Why?
| | Africa, Western | 1 | 2018 | 21 | 0.140 |
Why?
| | Computed Tomography Angiography | 1 | 2019 | 146 | 0.140 |
Why?
| | Sexual and Gender Minorities | 1 | 2022 | 259 | 0.140 |
Why?
| | Vancomycin | 3 | 2025 | 94 | 0.140 |
Why?
| | Stroke Volume | 1 | 2021 | 654 | 0.140 |
Why?
| | Raw Foods | 1 | 2018 | 3 | 0.140 |
Why?
| | Administration, Intravenous | 1 | 2019 | 172 | 0.140 |
Why?
| | Sex Factors | 1 | 2024 | 2105 | 0.140 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 542 | 0.130 |
Why?
| | Itraconazole | 1 | 2017 | 8 | 0.130 |
Why?
| | Prisoners | 1 | 2020 | 142 | 0.130 |
Why?
| | Adolescent | 7 | 2026 | 22529 | 0.130 |
Why?
| | California | 1 | 2019 | 471 | 0.130 |
Why?
| | Food Microbiology | 1 | 2018 | 39 | 0.130 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 157 | 0.130 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 340 | 0.130 |
Why?
| | Time Factors | 2 | 2019 | 7123 | 0.130 |
Why?
| | Administration, Oral | 2 | 2020 | 866 | 0.130 |
Why?
| | Hyponatremia | 1 | 2018 | 43 | 0.130 |
Why?
| | Arrhythmias, Cardiac | 1 | 2020 | 355 | 0.130 |
Why?
| | Cytokines | 2 | 2022 | 2067 | 0.130 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2953 | 0.130 |
Why?
| | Neoplasms | 1 | 2013 | 2906 | 0.130 |
Why?
| | Respiration, Artificial | 1 | 2022 | 713 | 0.130 |
Why?
| | Disability Evaluation | 1 | 2019 | 310 | 0.130 |
Why?
| | Research Design | 2 | 2021 | 1137 | 0.120 |
Why?
| | Farmers | 1 | 2017 | 71 | 0.120 |
Why?
| | Arachis | 1 | 2017 | 108 | 0.120 |
Why?
| | Mebendazole | 1 | 2016 | 2 | 0.120 |
Why?
| | Strongyloides | 1 | 2016 | 2 | 0.120 |
Why?
| | Trichuris | 1 | 2016 | 3 | 0.120 |
Why?
| | Albendazole | 1 | 2016 | 5 | 0.120 |
Why?
| | Patient Safety | 1 | 2020 | 356 | 0.120 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 261 | 0.120 |
Why?
| | Ivermectin | 1 | 2016 | 15 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 740 | 0.120 |
Why?
| | Hematocrit | 1 | 2016 | 108 | 0.120 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1323 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2020 | 776 | 0.120 |
Why?
| | Hospitals, University | 1 | 2016 | 176 | 0.120 |
Why?
| | Praziquantel | 1 | 2015 | 5 | 0.120 |
Why?
| | Pharmacists | 1 | 2019 | 258 | 0.120 |
Why?
| | Anthelmintics | 1 | 2015 | 12 | 0.110 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 881 | 0.110 |
Why?
| | Clone Cells | 1 | 2016 | 263 | 0.110 |
Why?
| | Brain | 1 | 2008 | 2947 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1508 | 0.110 |
Why?
| | Genotype | 2 | 2012 | 1852 | 0.110 |
Why?
| | Disease Outbreaks | 3 | 2023 | 419 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1138 | 0.110 |
Why?
| | Academic Medical Centers | 1 | 2018 | 554 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 484 | 0.110 |
Why?
| | Herpesvirus 4, Human | 1 | 2015 | 172 | 0.110 |
Why?
| | Health Care Costs | 1 | 2018 | 425 | 0.110 |
Why?
| | Frontal Lobe | 1 | 2015 | 160 | 0.100 |
Why?
| | Migraine Disorders | 1 | 2016 | 114 | 0.100 |
Why?
| | Biopsy | 2 | 2020 | 1082 | 0.100 |
Why?
| | Mycobacterium leprae | 2 | 2026 | 9 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 167 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1547 | 0.100 |
Why?
| | Hearing Loss | 1 | 2018 | 249 | 0.100 |
Why?
| | Lipids | 1 | 2019 | 707 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2021 | 946 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5904 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2020 | 680 | 0.100 |
Why?
| | Hemoglobins | 1 | 2016 | 386 | 0.100 |
Why?
| | Parasite Load | 1 | 2013 | 10 | 0.100 |
Why?
| | Mycoplasma hominis | 1 | 2012 | 4 | 0.100 |
Why?
| | Intestines | 1 | 2016 | 354 | 0.100 |
Why?
| | APACHE | 1 | 2013 | 68 | 0.100 |
Why?
| | Mycoplasma Infections | 1 | 2012 | 17 | 0.090 |
Why?
| | Klebsiella Infections | 1 | 2013 | 26 | 0.090 |
Why?
| | Health Status Disparities | 3 | 2020 | 321 | 0.090 |
Why?
| | Platelet Count | 1 | 2013 | 94 | 0.090 |
Why?
| | Clindamycin | 1 | 2012 | 14 | 0.090 |
Why?
| | Molecular Typing | 1 | 2012 | 21 | 0.090 |
Why?
| | Intensive Care Units | 3 | 2025 | 924 | 0.090 |
Why?
| | Syncope | 1 | 2013 | 56 | 0.090 |
Why?
| | Logistic Models | 1 | 2018 | 2134 | 0.090 |
Why?
| | Disease Progression | 2 | 2012 | 2864 | 0.090 |
Why?
| | Serratia Infections | 1 | 2012 | 8 | 0.090 |
Why?
| | Linkage Disequilibrium | 1 | 2013 | 253 | 0.090 |
Why?
| | Serratia marcescens | 1 | 2012 | 17 | 0.090 |
Why?
| | Feces | 1 | 2015 | 495 | 0.090 |
Why?
| | Central America | 2 | 2023 | 28 | 0.090 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1261 | 0.090 |
Why?
| | Disease Eradication | 2 | 2022 | 7 | 0.090 |
Why?
| | Thoracic Vertebrae | 1 | 2012 | 82 | 0.090 |
Why?
| | Hedgehog Proteins | 1 | 2013 | 200 | 0.090 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2013 | 124 | 0.090 |
Why?
| | Blister | 1 | 2011 | 39 | 0.090 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2015 | 534 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2012 | 76 | 0.090 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 43 | 0.090 |
Why?
| | Microscopy | 1 | 2013 | 147 | 0.080 |
Why?
| | Anti-HIV Agents | 2 | 2024 | 912 | 0.080 |
Why?
| | Poliovirus Vaccine, Oral | 2 | 2022 | 25 | 0.080 |
Why?
| | Viral Load | 2 | 2024 | 526 | 0.080 |
Why?
| | Soft Tissue Infections | 1 | 2011 | 40 | 0.080 |
Why?
| | Venezuela | 2 | 2021 | 7 | 0.080 |
Why?
| | Drug Resistance, Viral | 1 | 2012 | 126 | 0.080 |
Why?
| | Myocardium | 1 | 2016 | 934 | 0.080 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 185 | 0.080 |
Why?
| | HIV Seropositivity | 1 | 2011 | 119 | 0.080 |
Why?
| | Prevalence | 1 | 2018 | 2865 | 0.080 |
Why?
| | Gene Expression | 1 | 2015 | 1476 | 0.080 |
Why?
| | Coinfection | 1 | 2012 | 143 | 0.080 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2013 | 238 | 0.080 |
Why?
| | Cross Infection | 1 | 2013 | 260 | 0.080 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 177 | 0.080 |
Why?
| | Penicillanic Acid | 1 | 2009 | 4 | 0.080 |
Why?
| | Piperacillin | 1 | 2009 | 7 | 0.080 |
Why?
| | Urinary Tract Infections | 1 | 2012 | 210 | 0.080 |
Why?
| | Bacterial Typing Techniques | 1 | 2009 | 40 | 0.080 |
Why?
| | Mice | 3 | 2023 | 18329 | 0.070 |
Why?
| | Debridement | 1 | 2009 | 85 | 0.070 |
Why?
| | Surgical Wound Infection | 1 | 2012 | 329 | 0.070 |
Why?
| | Hypertension | 1 | 2018 | 1273 | 0.070 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 232 | 0.070 |
Why?
| | Spinal Cord Injuries | 1 | 2012 | 234 | 0.070 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 428 | 0.070 |
Why?
| | Genes, Dominant | 1 | 2008 | 100 | 0.070 |
Why?
| | Socialization | 1 | 2018 | 23 | 0.070 |
Why?
| | Chromosome Disorders | 1 | 2008 | 47 | 0.070 |
Why?
| | Needs Assessment | 2 | 2021 | 402 | 0.070 |
Why?
| | Mortality | 2 | 2021 | 378 | 0.070 |
Why?
| | Genetic Markers | 1 | 2008 | 335 | 0.060 |
Why?
| | Point Mutation | 1 | 2008 | 240 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 302 | 0.060 |
Why?
| | DNA Mutational Analysis | 1 | 2008 | 407 | 0.060 |
Why?
| | Pedigree | 1 | 2008 | 515 | 0.060 |
Why?
| | Gene Frequency | 1 | 2008 | 487 | 0.060 |
Why?
| | Leprostatic Agents | 1 | 2026 | 6 | 0.060 |
Why?
| | Chronic Disease | 1 | 2012 | 1808 | 0.060 |
Why?
| | Anemia, Hemolytic | 1 | 2026 | 21 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2597 | 0.060 |
Why?
| | Amyloid beta-Peptides | 1 | 2008 | 244 | 0.060 |
Why?
| | New York City | 1 | 2025 | 84 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2158 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 599 | 0.060 |
Why?
| | Genetic Testing | 1 | 2008 | 480 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2012 | 925 | 0.050 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 978 | 0.050 |
Why?
| | Antivenins | 1 | 2024 | 29 | 0.050 |
Why?
| | Moths | 1 | 2024 | 45 | 0.050 |
Why?
| | Aminobutyrates | 1 | 2024 | 31 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2008 | 693 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2012 | 961 | 0.050 |
Why?
| | Ribonucleosides | 1 | 2023 | 7 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2018 | 910 | 0.050 |
Why?
| | Drug Substitution | 1 | 2024 | 63 | 0.050 |
Why?
| | Acetazolamide | 1 | 2023 | 26 | 0.050 |
Why?
| | Antibodies, Protozoan | 1 | 2023 | 41 | 0.050 |
Why?
| | Registries | 1 | 2013 | 2406 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 5983 | 0.050 |
Why?
| | Tetrazoles | 1 | 2023 | 50 | 0.050 |
Why?
| | Human Rights | 1 | 2023 | 19 | 0.050 |
Why?
| | Biphenyl Compounds | 1 | 2023 | 67 | 0.050 |
Why?
| | HIV Integrase Inhibitors | 1 | 2024 | 79 | 0.050 |
Why?
| | Panama | 1 | 2022 | 11 | 0.050 |
Why?
| | Medicine, Traditional | 1 | 2022 | 23 | 0.050 |
Why?
| | Yellow fever virus | 1 | 2022 | 4 | 0.050 |
Why?
| | Monkeypox virus | 1 | 2022 | 23 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 187 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 81 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2023 | 265 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2823 | 0.050 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2022 | 27 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 1 | 2023 | 280 | 0.050 |
Why?
| | Benzimidazoles | 1 | 2023 | 189 | 0.050 |
Why?
| | Sex Offenses | 1 | 2025 | 196 | 0.050 |
Why?
| | Mexico | 1 | 2022 | 233 | 0.040 |
Why?
| | Cameroon | 1 | 2021 | 8 | 0.040 |
Why?
| | Cuba | 1 | 2021 | 15 | 0.040 |
Why?
| | Violence | 1 | 2025 | 279 | 0.040 |
Why?
| | Contact Tracing | 1 | 2021 | 26 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2023 | 364 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2022 | 219 | 0.040 |
Why?
| | Adenine | 1 | 2024 | 339 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4560 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2214 | 0.040 |
Why?
| | Dogs | 1 | 2022 | 458 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 6066 | 0.040 |
Why?
| | Minority Health | 1 | 2021 | 18 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 231 | 0.040 |
Why?
| | Curriculum | 1 | 2018 | 1070 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2025 | 1038 | 0.040 |
Why?
| | Cardiovascular Infections | 1 | 2020 | 1 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 10 | 0.040 |
Why?
| | History, 17th Century | 1 | 2020 | 14 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 171 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 284 | 0.040 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.040 |
Why?
| | Social Justice | 1 | 2021 | 81 | 0.040 |
Why?
| | Crowding | 1 | 2020 | 37 | 0.040 |
Why?
| | Inflammation | 2 | 2022 | 2878 | 0.040 |
Why?
| | Policy Making | 1 | 2020 | 83 | 0.040 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2024 | 440 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 85 | 0.040 |
Why?
| | Brazil | 1 | 2020 | 179 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 447 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 222 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 5216 | 0.040 |
Why?
| | Catheter-Related Infections | 1 | 2020 | 96 | 0.040 |
Why?
| | Frail Elderly | 1 | 2020 | 136 | 0.040 |
Why?
| | Hemorrhage | 1 | 2024 | 822 | 0.040 |
Why?
| | Cough | 1 | 2020 | 124 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 328 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2023 | 451 | 0.040 |
Why?
| | Southeastern United States | 1 | 2018 | 37 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 342 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2020 | 186 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2020 | 152 | 0.030 |
Why?
| | Drug Compounding | 1 | 2019 | 107 | 0.030 |
Why?
| | Nursing Homes | 1 | 2020 | 174 | 0.030 |
Why?
| | HIV-1 | 1 | 2024 | 908 | 0.030 |
Why?
| | Immunologic Factors | 1 | 2020 | 260 | 0.030 |
Why?
| | Risk | 1 | 2020 | 919 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2022 | 308 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1041 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2020 | 375 | 0.030 |
Why?
| | Urban Population | 1 | 2020 | 493 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 558 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 732 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 900 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 355 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3922 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 992 | 0.030 |
Why?
| | Mass Screening | 1 | 2022 | 1360 | 0.030 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2012 | 22 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2012 | 73 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3747 | 0.020 |
Why?
| | Infant | 1 | 2021 | 10077 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2028 | 0.020 |
Why?
| | Lung | 1 | 2020 | 4106 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 11853 | 0.010 |
Why?
|
|
Henao Martinez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|